Vimta Labs Limited has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, following a Board meeting held on January 28, 2026. For the quarter ended December 31, 2025, the company reported a revenue from operations of 986.33 million, representing a 3.16% decrease from the previous quarter’s 1,018.48 million but a 9.69% increase compared to 899.23 million in the corresponding quarter of the previous year. The profit for the period from continuing operations stood at 175.86 million, showing an 11.72% decline from 199.20 million in the previous quarter and a marginal 0.40% increase from 175.16 million in the same quarter last year. This performance was impacted by an exceptional item of 16.16 million related to the implementation of new labour codes.

Vimta Labs Limited is a leading India-based contract research and testing organization that provides a comprehensive range of services to the pharmaceutical, biopharmaceutical, food, consumer products, and environmental sectors. Established in 1984, the company specializes in analytical testing, clinical research, preclinical studies, and environmental assessments. In 2025, Vimta Labs has continued to strengthen its market position, recently highlighting its ongoing Public Private Partnership with the Food Safety and Standards Authority of India (FSSAI) to operate the National Food Testing Laboratory in JNPT, Mumbai. The company also recently completed the divestment of its diagnostic and pathological services business to Thyrocare Technologies Limited, focusing its efforts on its core contract research and testing operations. Notable investor interest in the company remains steady, with the promoter group holding a significant stake as of the latest 2025 filings.